Clinical Trials in Chicago

Showing 4321-4340 of 9,860 trials

Bioavailability of EPA + DHA in a SMEDS Formulation

NCT03443076

This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation compared with a standard omega-3-acid ethyl ester product in healthy men and women.

Bioavailability

Midwest Center for Metabolic and Cardiovascular Research24 participantsStarted Feb 2018

Boca Raton, Florida, United States • Chicago, Illinois, United States

TERMINATEDNA2.2 miles

OPTIMIZE IDE for the Treatment of ACS

NCT03190473

Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length with a reference vessel diameter of 2.25 mm - 4.00 mm

Acute Coronary Syndrome

Svelte Medical Systems, Inc.1,630 participantsStarted Jan 2018

Fairhope, Alabama, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +69 more locations

Bioavailability of EPA + DHA in a SMEDS Formulation

OPTIMIZE IDE for the Treatment of ACS

Find Trials by Condition in Chicago

Efficacy of Naltrexone in Women's Smoking Cessation

Evaluation of the CleanSweep™ Closed Suction System on Length of Mechanical Ventilation and Ventilator-Associated Events

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Assessment of Acute Disease to Reduce Imaging Costs

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

The TREFOIL Concept 5 Year Clinical Investigation